Synonyms: MP 470 | MP-470 | MP470
Compound class:
Synthetic organic
Comment: Amuvatinib is an orally bioavailable, multitargeted receptor tyrosine kinase inhibitor. Some bioactivity data may be associated with the hydrochloride salt (PubChem CID 67254077).
|
|
No information available. |
Summary of Clinical Use ![]() |
A Phase 2 clinical trial for small cell lung cancer (in combination with platinum-etoposide chemotherapy) was registered with ClinicalTrials.gov, but details have not been updated since 2012. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Amuvatinib binds to and inhibits the activity of mutant forms of the stem cell factor receptor (c-Kit, mutant forms of which are often associated with tumor chemoresistance [2]), AXL [2] and other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFRα, which are frequently dysregulated in variety of tumours. In addition, this compound suppresses the induction of the DNA repair protein RAD51 recombinase (HGNC ID 9817), thereby potentiating the activities of DNA damage-inducing agents [3-4]. |